For 25 years since its founding, GM PHARMA - an international pharmaceutical company has consistently held a leading position in the region. The company summarized the year with exceptional results - it successfully passed the Good Manufacturing Practice (GMP) inspection by the Eurasian Economic Union (EAEU), once again proving that its main priority is high quality and compliance with international standards.

It is also noteworthy that GM PHARMA not only successfully passed the Eurasian audit, but the entire inspection and evaluation process was completed without any remarks. This achievement belongs to every member of the company's team and is the result of their dedication and professionalism. The GMP inspectors of the Eurasian Economic Union (EAEU) - specifically from Kazakhstan’s regulatory authority spent four days at the company.

Successfully passing the EAEU GMP audit is one of the most important strategic achievements for a pharmaceutical company. The Eurasian Economic Union unites Kazakhstan, Armenia, Kyrgyzstan, Belarus and Russia. Obtaining the EAEU GMP certificate means that the manufacturing facility fully complies with the pharmaceutical regulatory requirements of this region.

The EAEU GMP standard is recognized not only at the regional level but also internationally and it is fully aligned with the European Union’s GMP directives and the requirements of the World Health Organization. Successfully passing this audit confirms that the company manufactures medicines in accordance with high standards of quality, safety and efficacy. This strengthens the trust of regulatory authorities, as well as that of partners and distributors.

At the same time, successfully passing the audit simplifies the certification and registration processes in all countries where the EAEU GMP standard is mandatory. It significantly reduces the time and costs required to enter new markets, giving the company a strong competitive advantage.

The preparation process for the EAEU GMP audit requires optimization of manufacturing, quality control and documentation systems. Successfully passing the audit reflects a high level of internal quality culture within the company, as well as transparency and efficiency of processes, all of which are essential for the long-term production of high-quality pharmaceutical products.

GMP certification is not only a mandatory regulatory requirement but also a reflection of the trust that patients, healthcare professionals and partners place in the company. Successfully passing the EAEU GMP audit means that the company is ready for international competition and has the potential to become a global pharmaceutical player. This aligns with the company’s strategic goal expanding its business activities into the countries of Europe, Southeast Asia and South and Central America.

It should be noted that GM PHARMA is the leading and only global pharmaceutical company originating from Georgia, with medicines and food supplements manufactured in GMP-certified manufacturing plants in Western European countries (Germany, Greece, Spain, Switzerland, Italy, Sweden, Portugal) and in its own GMP-certified manufacturing plant in Georgia.

Importantly, the company holds all national and international certificates and permits required for pharmaceutical manufacturing, including Georgia’s national GMP certificate, international PIC/S and EAEU GMP certificates, ISO 9001:2017, ISO 17025 and others.

Since its establishment, the company’s mission and values have remained unchanged - continuous improvement of quality and products based on scientific approaches and industry best practices, as well as the manufacturing and delivery of medicines that enhance patients’ quality of life and extend their lives.

GM PHARMA - serving those who need it most!

(AD)